Enovis Launches New Veterinary Laser Therapy System in the U.S.

Enovis™ Corporation, an innovation-driven medical technology company, today announced the U.S. launch of CT-RevitL™, the next-generation veterinary PBM laser therapy system from its Companion Animal Health business. CT-RevitL delivers enhanced clinical performance, greater mobility and a more intuitive treatment experience for veterinary teams and their patients.

Laser therapy is one of the fastest-growing modalities in veterinary medicine, used to manage pain, accelerate tissue healing, reduce inflammation and support post-operative recovery across a wide range of musculoskeletal and soft-tissue conditions.¹ As pet owners increasingly seek drug-sparing alternatives and practices look for tools that improve both clinical outcomes and practice efficiency, demand for advanced laser therapy continues to grow.²

Companion Animal Health, an Enovis business and the U.S. market leader in veterinary therapeutic laser technology, has spent more than 15 years advancing the science and clinical application of PBM laser therapy. CT-RevitL uses Companion’s new COMPASS technology, an intelligent treatment guidance system that delivers precise, calibrated dosing to help reduce treatment variability and support consistent application across users. By making high-powered laser therapy simpler to deliver and easier to integrate into everyday practice workflows, COMPASS helps veterinary teams provide treatment with greater confidence and efficiency.³

"CT-RevitL represents the next chapter in our commitment to deliver practical, innovative, evidence-based veterinary care," said Terry Ross, Group President of Enovis’ Prevention & Recovery business segment, which includes Companion Animal Health. "We have been the trusted partner of veterinary teams across the U.S. for nearly two decades, and CT-RevitL extends that leadership by giving practitioners a more intuitive and consistent way to deliver laser therapy. It is a meaningful step forward for the pets we care for, the practices that rely on us, and the broader advancement of laser therapy as a standard of care in veterinary medicine."

Beyond its clinical applications, CT-RevitL is designed to support practice growth by expanding treatment offerings, encouraging repeatable protocols and helping practices generate recurring demand for non-drug care. By supporting routine use across a broad range of conditions, the system can help practices improve return on investment, strengthen client satisfaction and differentiate themselves as providers of advanced veterinary care.

CT-RevitL is available to veterinary practices across the United States beginning July 13, 2026, with international availability anticipated in subsequent phases. The launch is supported by a comprehensive clinical education program and ongoing partnership from Companion’s veterinary specialists. For more information, visit www.companionanimalhealth.com/RevitL.